CABOMETYX 60 mg film-coated tablets
Sponsors
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Universitaetsmedizin Goettingen, Grupo Espanol De Tumores Neuroendocrinos, Ipsen Pharma, Exelixis Inc.
Conditions
Advance Radioactive-Iodine Refractory Differentiated Thyroid CancerAdvanced solid tumorHepatocellular carcinomaLocally Advanced or Metastatic Renal Cell Carcinoma with a Clear-Cell Component Who Progressed After 1st Line Treatment with Checkpoint InhibitorsMetastatic Medullary Thyroid CancerMetastatic non-clear cell renal cell carcinomaMultiple myelomaNeuroendocrine Neoplasia
Neuroendocrine Tumor
Phase 2
Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.
CompletedCTIS2024-511292-15-00
Start: 2023-05-25End: 2025-11-30Target: 41Updated: 2024-03-05
A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)
RecruitingCTIS2023-509152-33-00
Start: 2016-07-25Target: 3000Updated: 2025-12-19
A PHASE II, MULTICENTRE, OPEN-LABEL STUDY OF CABOZANTINIB AS 2ND LINE TREATMENT IN SUBJECTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH A CLEAR-CELL COMPONENT WHO PROGRESSED AFTER 1ST LINE TREATMENT WITH CHECKPOINT INHIBITORS
Active, not recruitingCTIS2024-514479-16-00
Start: 2019-10-28Target: 6Updated: 2025-10-07
CABONEN – a phase II trial of Cabozantinib in patients with advanced, low proliferative NEN G3
Active, not recruitingCTIS2024-510863-50-00
Start: 2021-04-23Target: 45Updated: 2025-11-20
Efficacy and safety of Cabozantinib in patients with hepatocellular carcinoma progressing on or intolerant to prior treatment with immune checkpoint inhibitors: A phase II study (Immunocabo)
CompletedCTIS2024-516972-14-00
Start: 2020-01-30End: 2025-06-19Target: 46Updated: 2024-10-28
A phase II trial of an individualized treatment strategy for patients with metastatic non-clear cell renal carcinoma
Active, not recruitingCTIS2024-519070-39-00
Start: 2020-03-06Target: 30Updated: 2024-10-31
Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET
deregulation
Not yet recruitingCTIS2024-518386-95-02
Updated: 2026-01-09
Phase 3
A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy
Active, not recruitingCTIS2024-516479-34-00
Start: 2019-05-17Target: 7Updated: 2025-11-04
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy
Active, not recruitingCTIS2024-516478-31-00
Start: 2019-06-12Target: 6Updated: 2025-09-16